BUY Zydus Lifesciences Limited — Prakash Gaba
byPrakash GabaHorizon: BTST11 Aug 2026, 3:14 pm ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic
NSE · Press Release·11 Aug · today
Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc
BSE · Company Update·11 Aug · today
Zydus Lifesciences Q1 Results: Stock jumps over 6%; India biz leads growth
NewsCnbc-Tv18·11 Aug · today
Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth
NewsNdtv-Profit·11 Aug · yesterday
Zydus Lifesciences Ltd has launched REVAHALE, which is India's first once-daily nebulised LAMA medication for COPD.
BSE · Company Update·10 Aug · yesterday
Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.
NSE · Press Release·11 Aug · today
Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.
BSE · Company Update·11 Aug · today
Unaudited financial results for the quarter ended on June 30, 2026
BSE · Board Meeting·11 Aug · today
Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price
NewsNdtv-Profit·11 Aug · yesterday
Market Pulse: Key triggers to watch before the August 11 trading session
NewsCnbc-Tv18·10 Aug · yesterday
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.